<DOC>
	<DOCNO>NCT01029886</DOCNO>
	<brief_summary>No head head comparison exenatide weekly liraglutide perform . Therefore , purpose study compare exenatide weekly once-daily liraglutide regard HbA1c , body weight , subject-reported outcome , clinical benefit . The study include 26-week treatment period safety follow-up visit 10 week final study drug dose .</brief_summary>
	<brief_title>Safety Efficacy Exenatide Once Weekly Versus Liraglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed type 2 diabetes Have suboptimal glycemic control evidence HbA1c measurement study start 7.1 % 11.0 % , inclusive Have body mass index ( BMI ) ≤45 kg/m^2 Have treat lifestyle modification ( diet exercise ) one follow single oral antidiabetic agent ( OADs ) combination OADs administer maximum tolerated dose : metformin SU metformin plus SU metformin plus pioglitazone Have contraindication , allergy , hypersensitivity study drug ( exenatide weekly liraglutide ) , exenatide twice daily , OAD ( ) use , excipients contain agent If take metformin contraindication metformin use Have treat within 8 week study start systemic glucocorticoid therapy oral , intravenous , intraarticular , intramuscular route Have treat drug promote weight loss ( e.g. , Xenical® [ orlistat ] , Meridia® [ sibutramine ] , Acomplia® [ rimonabant ] , Acutrim® [ phenylpropanolamine ] , similar overthecounter medication ) within 3 month study start Have take follow excluded medication 1 week within 3 month prior study start , take follow excluded medication within 1 month prior study start : Insulin Alphaglucosidase inhibitor ( e.g. , Glyser® [ miglitol ] Precose® [ acarbose ] ) Meglitinides ( e.g. , Prandin® [ repaglinide ] Starlix® [ nateglinide ] ) Avandia® ( rosiglitazone ) Dipeptidyl peptidase ( DPP ) 4 inhibitor ( e.g. , Januvia™ [ sitagliptin ] , Galvus® [ vildagliptin ] , Onglyza™ [ saxagliptin ] ) Symlin® ( pramlintide acetate ) Have donate blood within 30 day prior study start blood transfusion severe blood loss within 3 month prior study start Have time , include clinical trial , take exenatide weekly , exenatide twice daily , liraglutide , GLP1 receptor agonist GLP1 analog Are currently enrol , discontinue within last 3 month longer require local guideline , clinical trial involve use investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study Have previously screenfailed study reason If subject discontinues metformin , sulfonylurea , pioglitazone prior screening , subject include discontinue medication ( whether alone component combined medication ) accord specific schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>liraglutide</keyword>
	<keyword>Victoza</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>